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bjectives Review the use of drug-eluting stents (DES) to evaluate changes in use.
ackground The DES were approved after several small studies in carefully selected patients
howed dramatic reduction in in-stent restenosis. The DES were then rapidly adopted into routine
ractice. In 2006, 3 years after introduction, serious concerns regarding long-term safety were raised.
ethods We queried the American College of Cardiology/National Cardiovascular Data Registry (ACC/NCDR)
athPCI Registry. The percentage of DES used through mid-2009 was reviewed overall and in subgroups of
atients categorized by lesion type, clinical factors, insurance, and hospital characteristics. Multivariable logistic
odels relating these covariates to DES usage were constructed for 3 relevant time intervals.
esults A total of 2,247,647 coronary stent procedures were analyzed. By 2005 over 90% of ﬁrst
tents placed were DES. Safety concerns arising in 2006 reduced DES use to 64% of ﬁrst stent
laced. After publication of salutary outcomes data in 2008, usage increased to 76% by mid-2009.
he logistic models demonstrated decreased likelihood of DES usage in patients with: 1) ST-segment
levation myocardial infarctions; and 2) no medical insurance. The DES usage increased for in-stent
estenosis. Hospital characteristics were not associated with signiﬁcant differences in DES usage.
onclusions There was rapid adoption of DES into U.S. clinical practice. Concern for late stent thrombo-
is in 2006 signiﬁcantly altered DES use with reductions seen in subgroups at risk for thrombosis and
atients with no insurance. These rapid cyclic changes after DES introduction reinforce the need for continu-
us, timely reporting of outcomes data after the introduction of new technologies. (J Am Coll Cardiol Intv
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903olymer-coated stents eluting antiproliferative drugs (DES)
ere introduced to solve the problem of late restenosis of
he bare-metal stents (BMS) used in percutaneous coronary
nterventions (PCIs). Several small studies with highly
elected patients showed marked reduction in in-stent
estenosis (1,2), and these led to approval for use in the U.S.
hereafter, DES were rapidly incorporated into clinical
ractice (3). However, concerns were raised early about the
ossible thrombogenicity of DES (4–6). In mid-2006, a
eries of studies reporting increased stent thrombosis or
ven death after stopping antiplatelet therapy were pre-
ented (7–9) and were highly publicized (10). A Food and
rug Administration (FDA) Advisory Panel on the Safety
nd Efficacy of Drug-Eluting Stents then released a state-
ent recognizing a small but significant risk of late throm-
osis with DES but endorsed them as safe and effective
hen used in the lesion subsets in which the original use was
pproved (i.e., “on label”, simple straightforward lesions in
therwise healthy people) (11). However, over one-half of
tent implantations at that time were “off label” for which
here were no data (3). At the time of the FDA statement,
ore than 1,250,875 DES had been recorded in the
merican College of Cardiology National Cardiology Data
egistry (ACC/NCDR). Since 2007, multiple reports have
een published documenting the delayed endothelization of
ES and the potential for late stent thrombosis (12),
mphasizing the need for prolonged antiplatelet therapy
ith dual agents (DAPT) (9). More recently, a number of
arge studies have shown that the long-term risks are not
reater for DES compared with BMS (13–16) and might be
etter (17).
To investigate the impact of these issues on stent choice,
e accessed data from the ACC-NCDR (18). We specifi-
ally looked at DES usage in complex, “off label” lesions as
ell as in clinical subgroups that had been systematically
xcluded from the approval studies. Because of the financial
urden long-term DAPT might impose on patients and its
mportance in preventing late stent thrombosis, we also
ssessed the impact of medical insurance on DES place-
ent.
ethods
he ACC/NCDR Cath/PCI registry is a voluntary registry
hose purpose includes quality assessments of diagnostic
oronary angiography and percutaneous coronary interven-
ion procedures (18). Data were entered locally with ACC
ertified data entry software, into version 2.0 or 3.0, and
ransmitted to the database. Data were checked for consis-
ency and completeness before incorporation into the data-
ase. The data elements are available on the ACC website.
atient selection. Data from 945 hospitals participating in
he NCDR Cath/PCI registry from April 1, 2003 to July 1,
009, were analyzed. The type of stent used was evaluated. hnly the first PCI/hospital admission was considered. If
ny DES were used in the index PCI lab visit, then that lab
isit is considered “DES”. Thus, a patient could have
ultiple PCIs/admission, but the DES designation refers
nly to the first PCI of that admission. In addition to
nalysis of the population as a whole, analyses of subgroups
ere performed.
tatistical analysis. The number of DES and BMS for the
otal group and selected subgroups were evaluated each
uarter (Q) from 2003 until mid-2009, and the percentage
f DES was calculated. The comparisons of baseline fea-
ures (Table 1) were made with Pearson chi-square tests for
ategorical variables and Wilcoxon rank sum tests for
ontinuous variables. For the determination of factors inde-
endently associated with DES use, a list of patient and
ospital characteristics was entered into 3 multivariable
odels: “early-peak period” 2005 Q1 through 2006 Q2,
nadir” 2007 Q2 through 2008
2, and “late” 2008 Q4 through
009 Q2. The variables were
ge, sex, diabetes, indications for
he procedure (elective, non–
T-segment elevation acute cor-
nary syndrome [unstable an-
ina and non–ST-segment
levation myocardial infarction],
r ST-segment elevation myo-
ardial infarction [STEMI]),
ein grafts, chronic total occlu-
ions, de novo lesions or in-stent
estenosis, bifurcation lesions,
ospital size, annual PCI vol-
me, teaching hospital, location/
ommunity type, and hospital
wner. Type of medical insur-
nce was also reviewed, and the
o insurance group was com-
ared with: 1) government insurance (Veterans Adminis-
ration, Medicare, or Medicaid); and 2) private insurance or
MOs. In addition, because patients within a hospital are
ore likely to be treated in a similar way, generalized
stimating equation models with exchangeable working
orrelation structure were used to adjust for correlations
mong clustered responses (e.g., within hospital correla-
ions). The 95% confidence intervals and p values were
alculated for all listed variables for each time period.
esults
etween April 1, 2003 and July 1, 2009, a total of 2,247,647
oronary stent procedures were performed in participating
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BMS  bare-metal stent(s)
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
FDA  Food and Drug
Administration
OR  odds ratio
PCI  percutaneous
coronary intervention
Q  calendar quarter
STEMI  ST-segment
elevation myocardial
infarctionospitals. The DES usage rose from 0.1% of the total stent
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904Table 1. Comparison of Features of Patients With DES vs. BMS
Total (n  2,446,402) % Overall n  1,648,760 % DES n  797,642 % BMS % DES Used
Demographic data
Age (yrs)
Mean 64.28 64.04 64.77
Sex
Male 1,628,498 66.57 1,091,257 66.19 537,241 67.35 67.01
Female 817,904 33.43 557,503 33.81 260,401 32.65 68.16
Insurance
Missing 7,538 0.31 1,871 0.11 5,667 0.71 24.82
Government 1,270,835 51.95 843,111 51.14 427,724 53.62 66.34
Commercial 738,563 30.19 518,143 31.43 220,420 27.63 70.16
HMO 305,211 12.48 213,848 12.97 91,363 11.45 70.07
None 122,512 5.01 70,540 4.28 51,972 6.52 57.58
Non U.S. insurance 1,743 0.07 1,247 0.08 496 0.06 71.54
Diabetes
Missing 277 0.01 141 0.01 136 0.02 50.90
No diabetes 1,656,412 67.71 1,098,603 66.63 557,809 69.93 66.32
Diabetes 697,056 31.98 478,099 33.05 218,357 29.87 68.59
Hypertension
Missing 260 0.01 152 0.01 108 0.01 58.46
No 582,754 23.82 368,443 22.35 214,311 26.87 63.22
Yes 1,863,388 76.17 1,280,165 77.64 583,223 73.12 68.70
Tobacco history
Missing 495 0.02 295 0.02 200 0.03 59.60
Never 961,261 39.29 659,638 40.01 301,623 37.81 68.62
Yes-former 845,097 34.54 579,006 35.12 266,091 33.36 68.51
Yes-current 639,549 26.14 409,821 24.86 229,728 28.80 64.08
Dyslipidemia
Missing 444 0.02 234 0.01 210 0.03 52.70
No 631,656 25.82 383,204 23.24 248,452 31.15 60.67
Yes 1,814,302 74.16 1,265,322 76.74 548,980 68.83 69.74
Family history coronary artery disease: age 55 yrs
Missing 503 0.02 305 0.02 198 0.02 60.64
No 1,758,318 71.87 1,199,866 72.77 558,452 70.01 68.24
Yes 687,581 28.11 448,589 27.21 238,992 29.96 65.24
NYHA functional class (heart failure patients)
Missing 717 0.32 227 0.16 490 0.59 31.66
1 31,564 14.14 20,827 14.91 10,737 12.85 65.98
2 53,381 23.91 33,717 24.14 19,664 23.53 63.16
3 76,626 34.32 49,541 35.47 27,085 32.40 64.65
4 60,965 27.31 35,356 25.31 25,609 30.64 57.99
Admission symptoms
Missing 364 0.01 210 0.01 154 0.02 57.69
Presentation
No symptoms 302,434 12.36 212,149 12.87 90,285 11.32 70.15
Atypical pain 169,242 6.92 123,220 7.47 46,022 5.77 72.81
Stable angina 414,417 16.94 300,734 18.24 113,683 14.25 72.57
ACS: unstable angina 832,905 34.05 587,472 35.63 245,433 30.77 70.53
ACS: NSTEMI 384,942 15.74 244,197 14.81 140,745 17.65 63.44
ACS: STEMI 342,098 13.98 180,778 10.96 161,320 20.22 52.84Continued on next page
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905nsertions in 2003-Q1 to 86% by 2004-Q4 and remained
90% until 2006-Q3. Beginning in 2006-Q3, DES per-
entage fell dramatically, reaching its nadir of 64% in
007-Q4. By 2009-Q2 usage had increased to 76% of all
tents (Fig. 1). Patient demographic data are presented in
able 1.
Table 2 shows the multivariable logistic model for the
nsertion of a DES, and Figures 2 and 3 show usage patterns
ver time for selected variables. With the exception of
atients with in-stent restenosis and bifurcation lesions,
ES placement declined in all other off-label subgroups
Table 1. Continued
Total (n  2,446,402)
Lesion characteristics bypass grafts
Missing 475
No graft 2,284,942
Yes-artery 11,012
Yes-vein 149,973
In-stent restenosis
Missing 242
No 30,449
De novo 2,203,596
Restenosis 139,007
De novo/restenosis 63,720
Hospital features
Number of CMS-certiﬁed beds
Median 2,445,940
Location/missing 461
Community type
Rural 309,704
Suburban 665,571
Urban 1,470,666
Proﬁt type
Missing 461
Government 38,472
Private/community 2,182,199
University 225,270
Average annual PCI volume
Median 2,446,402
Hospital region
Missing 607,790
West 298,135
Northeast 229,253
Midwest 590,850
South 720,374
Teaching hospital
Missing 461
No 1,122,620
Yes 1,323,321
In all categories, bare-metal stent (BMS) versus drug-eluting stent (DES) and % DES used, p 0.000
ACS  acute coronary syndrome; NSTEMI  non–ST-segment myocardial infarction; NYHA  N
infarction.Table 2, Figs. 2A to 2D). (There was no significant difference in percentage of DES
sage for any of the hospital variables over the 3 time periods.
he logistic model demonstrated 3 groups where the odds
atio (OR) of DES usage changed significantly after 2006 (Fig.
, Table 2). The likelihood of usage in patients with in-stent
estenosis was increased at the early “peak period” 2005 Q1 to
006 Q2 (OR: 1.64), and the OR increased further over the
ast 2 periods (OR: 2.46 late period). The percentage use of
ES in patients with in-stent restenosis remained the highest
f all groups 88.5%% vs. 74.9% in Q2-2009, with DES
nsertion rates over 2.5 times more likely than BMS insertion
erall n  1,648,760 % DES n  797,642 % BMS % DES Used
.02 269 0.02 206 0.03 56.63
.40 1,556,119 94.38 728,823 91.37 68.10
.45 7,505 0.46 3,507 0.44 68.15
.13 84,867 5.15 65,106 8.16 56.59
.01 150 0.01 92 0.01 61.98
.24 18,422 1.12 12,027 1.51 60.50
.07 1,469,174 89.11 734,422 92.07 66.67
.68 107,821 6.54 31,186 3.91 77.57
.60 48,006 2.91 15,714 1.97 75.34
.00 1,648,692 427.00 797,248 430.00
.02 68 0.00 393 0.05 14.75
.66 196,646 11.93 113,058 14.17 63.49
.21 436,680 26.49 228,891 28.70 65.61
.12 1,015,366 61.58 455,300 57.08 69.04
.02 68 0.00 393 0.05 14.75
.57 27,099 1.64 11,373 1.43 70.44
.20 1,465,249 88.87 716,950 89.88 67.15
.21 156,344 9.48 68,926 8.64 69.40
.61 1,648,760 901.03 797,642 872.45
.84 235,559 14.29 372,231 46.67 38.76
.19 237,752 14.42 60,383 7.57 79.75
.37 169,909 10.31 59,344 7.44 74.11
.15 452,876 27.47 137,974 17.30 76.65
.45 552,664 33.52 167,710 21.03 76.72
.02 68 0.00 393 0.05 14.75
.89 770,155 46.71 352,465 44.19 68.60
.09 878,537 53.28 444,784 55.76 66.39
k Heart Association; PCI  percutaneous coronary intervention; STEMI  ST-segment myocardial% Ov
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906Patients with STEMIs had a substantially lower percentage
f DES implantation than patients with other indications
hroughout the entire period (Fig. 3A). The likelihood of DES
sage in STEMI dropped significantly after the FDA advisory,
ith the OR of DES insertion dropping from 0.55 to 0.39
Fig. 3C). Hospital insurance strongly influenced the likeli-
ood of a DES insertion. During the peak usage period,
atients with no insurance were two-thirds as likely to receive
Table 2. Multivariable Logistic Regression Models Relating Variables to Lik
Level OR
Early period January 1, 2005 to June 30, 2006
Saphenous vein grafts 0.43
STEMI vs. elective PCI 0.55
In-stent restenosis 1.64
No insurance vs. HMO 0.67
No insurance vs. commercial insurance 0.68
Bifurcation lesion 1.44
Chronic total occlusions 0.74
No insurance vs. government insurance 0.84
Age/10-yr increase 0.91
Female 1.13
NSTEACS vs. elective PCI 0.95
Diabetes 0.98
Government vs. private/community hospital 1.48
University vs. private/community hospital 1.20
Rural vs. urban hospital 1.10
Suburban vs. urban hospital 0.93
Teaching hospital vs. other 0.95
Certiﬁed hospital beds/100 increase 1.01
Annual PCI volume/100 increase 1.00
Nadir April 1, 2007 to March 31, 2008
STEMI vs. elective PCI 0.39
No insurance vs. commercial insurance 0.50
In-stent restenosis 2.40
No insurance vs. HMO 0.51
Saphenous vein grafts 0.58
Chronic total occlusions 0.73
Bifurcation lesion 1.39
No insurance vs. government insurance 0.63
Age/10-yr increase 0.91
NSTEACS vs. elective PCI 0.86
Female 1.09
Diabetes 1.07
Teaching hospital 0.87
Suburban vs. urban hospital 0.91
Certiﬁed beds/100 increase 0.97
University vs. private/community hospital 0.89
Rural vs. urban hospital 1.07
Government vs. private/community hospital 1.01
Annual PCI volume/100 increase 1.00DES as patients with insurance (OR: 0.67). This disparity wncreased after 2007, so that by the last period patients with no
nsurance were less than one-half as likely to get a DES as
atients with insurance (OR: 0.41) (Fig. 3B). Figure 3C graphs
Rs for each variable for each of the 3 periods. In-stent
estenosis, no insurance, and STEMIs were dramatically af-
ected in the decline period, out of proportion to the other
ariables. The ORs for the other variables did not change
ignificantly over the 3 periods (except saphenous vein grafts,
od of DES Implantation for the 3 Periods Monitored
Lower CL Upper CL p Value
0.41 0.46 0.0001
0.53 0.58 0.0001
1.51 1.80 0.0001
0.63 0.72 0.0001
0.64 0.72 0.0001
1.38 1.50 0.0001
0.71 0.77 0.0001
0.79 0.88 0.0001
0.90 0.93 0.0001
1.11 1.16 0.0001
0.92 0.98 0.0013
0.96 1.00 0.0574
0.88 2.46 0.1425
0.83 1.74 0.3344
0.85 1.43 0.4674
0.75 1.14 0.4765
0.77 1.18 0.6480
0.94 1.08 0.7759
0.98 1.02 0.9894
0.37 0.40 0.0001
0.48 0.52 0.0001
2.29 2.54 0.0001
0.49 0.53 0.0001
0.56 0.60 0.0001
0.71 0.75 0.0001
1.35 1.42 0.0001
0.61 0.65 0.0001
0.90 0.92 0.0001
0.84 0.87 0.0001
1.07 1.10 0.0001
1.06 1.09 0.0001
0.75 1.02 0.0911
0.77 1.07 0.2398
0.93 1.02 0.2847
0.68 1.16 0.3986
0.87 1.31 0.5194
0.68 1.49 0.9557
0.98 1.01 0.9690
Continued on next pageelihohich moved toward parity with native vessels).
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907iscussion
hese data document wide alterations in DES usage after
heir introduction in 2003. Initial rapid acceptance resulted
n peak usage in 2005 with DES accounting for 90% of all
tent implantations. A dramatic fall off in DES usage in late
006 coincided with increasing concern for late stent
hrombosis. Ultimately, DES usage increased in response to
eassuring safety data but failed to achieve peak usage rates
uring the height of enthusiasm in early 2006. This pattern
as also been shown in patients with non-STEMI from the
CTION (Acute Coronary Treatment and Intervention
utcomes Network) registry (19). From multivariable lo-
istic models used here, ORs for DES usage decreased over
he 3 specified time periods for STEMI patients and for
atients with no insurance but increased in patients with
n-stent restenosis. This suggests a more discriminating
pproach to DES placement (Fig. 3C) in response to
hanging safety data and an awareness of the importance of
rolonged DAPT.
Studies performed for new device approvals (or a new
harmaceutical) are designed to demonstrate efficacy and
afety, usually in the short term. In the case of DES,
pproval studies focused on the patients with lesions most
Lower CL Upper CL p Value
0.37 0.41 0.0001
0.39 0.43 0.0001
2.33 2.59 0.0001
0.39 0.43 0.0001
0.51 0.56 0.0001
0.73 0.77 0.0001
0.62 0.67 0.0001
0.89 0.90 0.0001
1.31 1.39 0.0001
0.85 0.90 0.0001
1.05 1.08 0.0001
1.02 1.06 0.0001
0.76 1.01 0.0653
0.62 1.02 0.0695
0.93 1.39 0.2198
0.74 1.79 0.5314
0.83 1.11 0.5643
0.95 1.03 0.6842
0.98 1.01 0.7504
ES in patients with in-stent restenosis and lower usage in patients with STEMIs and no insurance is
pital were significant in any period.
elevation acute coronary syndrome (unstable angina and non–ST-segment elevation myocardialFigure 1. DES as a Percentage of Total Stents Inserted
The results of the BASKET-LATE study (Basel Stent Cost-effectiveness trial-
Late Thrombotic Events) (7) and a meta-analysis by E. Camenzind were pre-
sented at the European Society of Cardiology Meeting in September 2006
(blue arrow). The Food and Drug Administration (FDA) statement was
published 2006-calendar quarter (Q)4 (red arrow). The 3 periods used for
calculation of the multivariable logistic models are indicated by the colored
bars. The time periods used for the calculation of the multivariable logisticTable 2. Continued
Level OR
Late period October 1, 2008 to June 30, 2009
STEMI vs. elective PCI 0.39
No insurance vs. commercial insurance 0.41
In-stent restenosis 2.46
No insurance vs. HMO 0.41
No insurance vs. government insurance 0.53
Chronic total occlusions 0.75
Saphenous vein grafts 0.65
Per 10-yr increase 0.90
Bifurcation lesion 1.34
NSTEACS vs. elective PCI 0.87
Diabetes 1.07
Female 1.04
Teaching hospital 0.87
University vs. private/community hospital 0.79
Rural vs. urban hospital 1.13
Government vs. private/community hospital 1.15
Suburban vs. urban hospital 0.96
Certiﬁed beds/100 increase 0.99
Annual PCI volume/100 increase 1.00
The variables are listed in the order of decreasing discrimination (odds ratio [OR]). The increased usage of D
noticed in the nadir period and continuing into the late period. None of the variables related to type of hos
CL  95% confidence level; HMO  health maintenance organization; NSTEACS  non–ST-segment
infarction); other abbreviations as in Table 1.ikely to demonstrate clearly and cleanly a reduction in
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908estenosis: simple, straightforward lesions in patent native
essels—excluding bifurcations, ostial lesions, calcified le-
ions, left main lesions, vessels 2.5 mm, or patients with
n-stent stenosis; all of this in patients free of higher risk
omorbidities, such as acute myocardial infarction or shock
1,2). The initial approval studies were not designed to
valuate long-term safety. Because DES prolong the period
f vulnerability to thrombosis by delaying stent endothe-
ization (20), the importance of prolonged DAPT shown to
educe stent thrombosis during the vulnerable period be-
ame apparent in 2004 with the publication of 4 case reports
f stent thrombosis within a few days of stopping DAPT
nd much later than would be expected—nearly 1 year after
ES implantation (6) . These initial concerns were height-
ned by the landmark BASKET-LATE study (Basel Stent
ost-effectiveness trial-Late Thrombotic Events) presented
t the European Cardiology Society meeting in 2006 (7). In
his study, patients were followed after the thienopyridine
omponent of DAPT, clopidogrel, was stopped at 6
onths. Increased rates of late stent thrombosis were
Figure 2. DES Usage by Off-Label Indications
(A) Drug-eluting stent (DES) usage for in-stent restenosis. (B) DES usage for ch
usage for bifurcation lesions. Data only available from database version 3, stareported, and DES usage dropped precipitously after this aeport. Then, beginning in 2007, studies showing a very low
ncidence of late stent thrombosis and infarction with DES
sage in a wide variety of patients while maintaining
uperiority over BMS in terms of target lesion revascular-
zation were published (16,21–23). Some studies, however,
ontinued to show a slight increased risk of thrombosis but
o increased mortality in patients receiving DES (24,25).
oinciding with recognition of the critical importance of
APT with DES usage, Spertus et al. (26) documented
hat nearly 14% of patients had stopped taking clopidogrel
ithin 30 days of receiving a DES for STEMI, with a
ubsequent 10-fold increase in mortality. These concerns
ere addressed in updated guidelines for PCI emphasizing
hat DAPT be continued for at least 1 year after DES
mplantation and that patients be screened “for the ability to
omply with the recommended . . . [DAPT] therapy” (27).
his update, offered in 2008 —5 years after the introduc-
ion of DES into the general U.S. market— coincided
ith the publication of a well-conceived FDA-mandated
ollow-up study emphasizing real world (i.e., off label)
total occlusion lesions. (C) DES usage for saphenous vein grafts. (D) DES
2004.ronicctivity 2008 (28).
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909We have documented that, after the FDA advisory in
006, DES usage became more selective and use increased
or in-stent restenosis and became less frequent in STEMI
nd in patients without medical insurance. The reasons
riving increased DES usage rates in 2009 are not clear
rom this analysis but might be related to the introduction of
econd-generation drug-eluting stents and the awareness of
he value of prolonged DAPT.
The experiences described here emphasize the inherent
ncertainty when new technologies are introduced to clin-
cal practice, especially when use is clearly going to go
utside of the patient populations included within the initial
pproval studies (11,29). Most approval studies are ade-
uately powered to prove efficacy but underpowered to
valuate safety (30). There is a clear need for aggressive
ost-market surveillance of new technologies with rapid
valuation and presentation of long-term results in real
orld populations and not just the patients similar to those
n the original approval studies that might only account for
fraction of patients actually receiving these technologies.
his might speed identification of concerns soon after
idespread adoption so that corrective actions can be taken,
r, as with DES, earlier recognition of the importance of
ong-term DAPT can be recommended before too many
atients are placed at risk.
tudy limitations. The ACC/NCDR is a voluntary national
egistry. Although not all interventional catheterization
aboratories in the U.S. participate, it is estimated that
pproximately 75% of coronary interventions are captured.
onclusions
ES were rapidly adopted into clinical practice in the U.S. on
he basis of studies showing efficacy against restenosis but that
ere underpowered to demonstrate long-term complications.
eports of late stent thrombosis surfacing 3 years after intro-
uction led to a dramatic reduction in usage, and DES
lacement became more selective after this point. In addition
o clinical criteria, the absence of health insurance greatly
nfluenced the likelihood that a DES would be placed, no
oubt related to the demonstration of the importance of
ontinuous DAPT therapy and the consequences of early
iscontinuation. The patterns of DES usage described
ere strongly reinforce the need for continuous timely
eporting of outcomes data after the introduction of new
echnologies to allow better understanding of the indica-
ions and precautions needed to assure optimal use and
afety as soon as possible after introduction.
eprint requests and correspondence: Dr. Ronald J. Krone,
ashington University School of Medicine, 660 South Euclid,
ampus Box 8086, St. Louis, Missouri 63110. E-mail:Figure 3. DES Usage by Indications, Medical Insurance, and Odds Ratios
From the Multivariable Logistic Analyses
(A) Drug-eluting stent (DES) usage by indications for the procedure.
(B) DES usage by medical insurance. (C) Odds ratios from the multivariable
logistic analyses (Table 2) for the 3 time periods. Note that the likelihood
of inserting a DES increased after 2007 for patients with in-stent restenosis
and decreased at that time for patients with ST-segment elevation myocar-
dial infarctions (STEMIs) and no insurance (NO INS). The likelihood of using
a DES in patients with saphenous veins also increased (but still less than in
the native vessel) after 2007. ACS  acute coronary syndrome; HMO 
health maintenance organization; Government  Veterans Administration,
Medicare, or Medicaid; None  no medical insurance; NSTEACS unstablekrone@wustl.edu.
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